SEARCH:   Advanced

Blood, 1 February 2005, Vol. 105, No. 3, pp. 948-958. Prepublished online as a Blood First Edition Paper on October 14, 2004; DOI 10.1182/blood-2004-03-0973. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-0973v1 105/3/948    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Woessmann, W. Articles by Reiter, A. Search for Related Content PubMed PubMed Citation Articles by Woessmann, W. Articles by Reiter, A. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95 Wilhelm Woessmann, Kathrin Seidemann, Georg Mann, Martin Zimmermann, Birgit Burkhardt, Ilske Oschlies, Wolf-Dieter Ludwig, Thomas Klingebiel, Norbert Graf, Bernd Gruhn, Heribert Juergens, Felix Niggli, Reza Parwaresch, Helmut Gadner, Hansjoerg Riehm, Martin Schrappe, and Alfred Reiter, for the BFM Group From the Department of Pediatric Hematology and Oncology, Justus-LiebigUniversity, Giessen, Germany; the Department of Pediatric Hematology and Oncology, Medizinische Hochschule, Hannover, Germany; St Anna Kinderspital, Vienna, Austria; the Institute of Hematopathology and Lymph Node Registry, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany; the Department of Hematology, Oncology, and Tumor Immunology, HELIOS Clinic Berlin-Buch, Charité, Campus Berlin-Buch, Berlin, Germany; the Department of Pediatric Hematology and Oncology, Johann-Wolfgang-Goethe University, Frankfurt, Germany; the Department of Pediatric Hematology and Oncology, University of Saarland, Homburg, Germany; the Department of Pediatrics, Friedrich Schiller University, Jena, Germany; the Department of Pediatric Hematology and Oncology, Westfaelische Wilhelms-University, Muenster, Germany; and the Department of Pediatrics, University of Zurich, Zurich, Switzerland. In the Non-Hodgkin Lymphoma–Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell neoplasms methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h). Second, we investigated against the historical control of study NHL-BFM90, whether for patients with moderate tumor mass MTX can be reduced from 5 g/m2 to 1 g/m2. Patients received 2 5-day therapy courses in risk group R1 (resected), 4 in R2 (lactate dehydrogenase [LDH] < 500 U/L), 5 in R3 (LDH > 500 to < 1000 U/L) and 6 in R4 (LDH > 1000 U/L and/or central nervous system [CNS] disease). Courses contained MTX 1 g/m2 in R1 + R2 and 5 g/m2 in R3 + R4. Of 505 patients (April 1996 to March 2001), 364 were randomized to receive MTX-4h or MTX-24h. Failure-free survival (pFFS, 1 year) for arm MTX-4h versus MTX-24h, respectively, was 95% ± 5% (n = 20) versus 100% (n = 19) in R1, 94% ± 2% (n = 88) versus 96% ± 2% (n = 95) in R2, and 77% ± 5% (n = 62) versus 93% ± 3% (n = 69) in R3 ± R4 (per-protocol analysis). Incidence of mucositis grade III/IV was significantly lower with MTX-4h in all risk groups. For patients in R2, event-free survival (pEFS) was 95% ± 2% (n = 222) in NHL-BFM95 (MTX 1 g/m2) and 97% ± 1% (n = 154) in NHL-BFM90 (MTX 5 g/m2). In conclusion, MTX-4h was less toxic than MTX-24h. MTX-4h was noninferior to MTX-24h for limited stage B-cell non-Hodgkin lymphoma (B-NHL) but not for advanced disease. For limited disease, MTX 1 g/m2 is noninferior to 5 g/m2. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. Klapper, M. Szczepanowski, B. Burkhardt, H. Berger, M. Rosolowski, S. Bentink, C. Schwaenen, S. Wessendorf, R. Spang, P. Moller, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials Blood, August 15, 2008; 112(4): 1374 - 1381. [Abstract] [Full Text] [PDF] L. Mussolin, M. Pillon, V. Conter, M. Piglione, L. Lo Nigro, P. Pierani, C. Micalizzi, S. Buffardi, G. Basso, L. Zanesco, et al. Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of Childhood J. Clin. Oncol., November 20, 2007; 25(33): 5254 - 5261. [Abstract] [Full Text] [PDF] J. Salzburg, B. Burkhardt, M. Zimmermann, O. Wachowski, W. Woessmann, I. Oschlies, W. Klapper, H.-H. Wacker, W.-D. Ludwig, F. Niggli, et al. Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-Munster Group Report J. Clin. Oncol., September 1, 2007; 25(25): 3915 - 3922. [Abstract] [Full Text] [PDF] R. H Scott, T. Homfray, N. L Huxter, S. G Mitton, R. Nash, M. N Potter, D. Lancaster, and N. Rahman Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations J. Med. Genet., July 1, 2007; 44(7): e83 - e83. [Abstract] [Full Text] [PDF] A. K. Fielding Be careful what you wish for? Blood, April 1, 2007; 109(7): 2673 - 2674. [Full Text] [PDF] C. Patte, A. Auperin, M. Gerrard, J. Michon, R. Pinkerton, R. Sposto, C. Weston, M. Raphael, S. L. Perkins, K. McCarthy, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients Blood, April 1, 2007; 109(7): 2773 - 2780. [Abstract] [Full Text] [PDF] M. S. Cairo, M. Gerrard, R. Sposto, A. Auperin, C. R. Pinkerton, J. Michon, C. Weston, S. L. Perkins, M. Raphael, K. McCarthy, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents Blood, April 1, 2007; 109(7): 2736 - 2743. [Abstract] [Full Text] [PDF] A. Reiter Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 285 - 296. [Abstract] [Full Text] [PDF] I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial Blood, May 15, 2006; 107(10): 4047 - 4052. [Abstract] [Full Text] [PDF] J. Sterba, L. Dusek, R. Demlova, and D. Valik Pretreatment Plasma Folate Modulates the Pharmacodynamic Effect of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: "Folate Overrescue" Concept Revisited Clin. Chem., April 1, 2006; 52(4): 692 - 700. [Abstract] [Full Text] [PDF] N. Gokbuget and D. Hoelzer Treatment of Adult Acute Lymphoblastic Leukemia Hematology, January 1, 2006; 2006(1): 133 - 141. [Abstract] [Full Text] [PDF] K. Seidemann, M. Zimmermann, M. Book, U. Meyer, B. Burkhardt, K. Welte, A. Reiter, and M. Stanulla Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkin's Lymphoma: Results From Berlin-Frankfurt-Munster Trial NHL-BFM 95 J. Clin. Oncol., November 20, 2005; 23(33): 8414 - 8421. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020